Winnebago Industries, Inc. (NYSE: WGO), a well-known manufacturer of recreational vehicles and marine products, reported adjusted earnings per share (EPS) of $2.13 for its its third-quarter fiscal 2023, surpassing the consensus estimate of $1.83.

However, the company's revenues for the quarter came in at $900.8 million, falling short of the consensus revenue estimate of $961.04 million. 

In pre-market, $WGO is currently trading at $61.86, down $2.32 (-3.61%). 

Shares of Chemomab Therapeutics Ltd. (Nasdaq: CMMB) surged in pre-market trading following the release of positive topline results from secondary analyses of its Phase 2a liver fibrosis trial. 

The trial evaluated CM-101, the company's groundbreaking CCL24-neutralizing antibody, in patients with non-alcoholic steatohepatitis (NASH), a liver disease characterized by fat accumulation in the liver.

The additional analyses revealed improvements in various inflammatory and fibrotic biomarkers, aligning with the favorable clinical outcomes previously reported by Chemomab in January. Notably, patients at higher risk of NASH progression demonstrated a more robust biomarker response to CM-101 treatment compared to those with lower-risk disease or those in the placebo group.

$CMMB is currently trading at $1.90 in pre-market, up $0.16 (+9.19%)

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)